What are the primary uses of Protonix 40 mg. How should it be dosed for various conditions. What are the potential side effects and interactions to be aware of. What precautions should be taken when using Protonix 40 mg.

Understanding Protonix 40 mg: A Powerful Proton Pump Inhibitor

Protonix 40 mg, also known by its generic name pantoprazole, is a potent proton pump inhibitor (PPI) used to treat various gastrointestinal conditions. This medication works by reducing the amount of acid produced in the stomach, providing relief from symptoms associated with acid-related disorders.

What is Protonix 40 mg used for?

Protonix 40 mg is primarily prescribed for the following conditions:

• Erosive Esophagitis (EE)
• Gastroesophageal Reflux Disease (GERD)
• Zollinger-Ellison Syndrome
• Pathological Hypersecretory Conditions

Dosage Guidelines for Protonix 40 mg in Adults

The dosage of Protonix 40 mg varies depending on the condition being treated and the patient’s individual needs. Here are the general dosage guidelines for adults:

Erosive Esophagitis Treatment

For the treatment of erosive esophagitis, the recommended dose is 40 mg orally once a day for 8 weeks. If healing is not complete after 8 weeks, an additional 8-week course may be considered.

GERD Treatment

For GERD treatment, the standard dose is 40 mg orally once a day for 8 weeks. In some cases, treatment may be extended for another 8 weeks if symptoms persist.

Zollinger-Ellison Syndrome and Pathological Hypersecretory Conditions

For these conditions, the initial dose is 40 mg orally twice a day. The maximum recommended daily dose is 240 mg.

Protonix 40 mg Usage in Pediatric Patients

Protonix 40 mg is also approved for use in pediatric patients aged 5 years and older for the treatment of erosive esophagitis and GERD. The dosage is based on the child’s weight:

• 15 to less than 40 kg: 20 mg orally once a day
• 40 kg and greater: 40 mg orally once a day

The duration of treatment for pediatric patients is up to 8 weeks. It’s important to note that safety has not been established for treatment beyond 8 weeks in children.

Special Dosing Considerations for Protonix 40 mg

While Protonix 40 mg is generally well-tolerated, certain patient populations may require dosage adjustments or special considerations:

Renal Impairment

No dosage adjustment is necessary for patients with renal impairment, including those undergoing hemodialysis.

Hepatic Impairment

For patients with severe hepatic impairment (Child-Pugh Class C), the maximum recommended dose is 20 mg daily.

Elderly Patients

No dosage adjustment is necessary based on age alone. However, elderly patients may be more sensitive to the effects of Protonix 40 mg and should be monitored closely.

Potential Side Effects of Protonix 40 mg

As with any medication, Protonix 40 mg may cause side effects in some patients. Common side effects include:

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Vomiting
• Flatulence
• Dizziness

While these side effects are generally mild and transient, patients should report any persistent or severe symptoms to their healthcare provider.

Are there any serious side effects associated with long-term use of Protonix 40 mg?

Long-term use of Protonix 40 mg, like other proton pump inhibitors, has been associated with certain risks:

• Increased risk of bone fractures
• Vitamin B12 deficiency
• Hypomagnesemia (low magnesium levels)
• Increased risk of Clostridium difficile-associated diarrhea
• Potential increased risk of kidney problems

Patients on long-term Protonix 40 mg therapy should be monitored regularly by their healthcare provider to assess the ongoing need for treatment and to watch for potential complications.

Drug Interactions with Protonix 40 mg

Protonix 40 mg can interact with several other medications, potentially altering their effectiveness or increasing the risk of side effects. Some notable interactions include:

Antiretroviral Drugs

Protonix 40 mg may reduce the absorption of certain antiretroviral drugs used to treat HIV, such as atazanavir and nelfinavir. Concurrent use is not recommended.

Warfarin

Concomitant use of Protonix 40 mg and warfarin may increase the risk of bleeding. Patients on this combination should be monitored closely for changes in INR and prothrombin time.

Methotrexate

Protonix 40 mg may increase serum levels of methotrexate. Temporary withdrawal of Protonix 40 mg should be considered in patients receiving high-dose methotrexate.

Clopidogrel

Protonix 40 mg may reduce the effectiveness of clopidogrel by interfering with its activation in the body. Alternative antiplatelet therapy should be considered in patients taking both medications.

Precautions and Warnings for Protonix 40 mg Use

While Protonix 40 mg is generally safe and effective when used as directed, there are several precautions and warnings to be aware of:

Gastric Malignancy

Symptomatic response to Protonix 40 mg does not preclude the presence of gastric malignancy. Appropriate diagnostic testing should be performed if gastric malignancy is suspected.

Acute Interstitial Nephritis

Acute interstitial nephritis has been observed in patients taking Protonix 40 mg. Discontinue the drug if acute interstitial nephritis develops.

Clostridium difficile-Associated Diarrhea

PPI therapy, including Protonix 40 mg, may be associated with an increased risk of Clostridium difficile-associated diarrhea. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

Bone Fracture

Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.

Cutaneous and Systemic Lupus Erythematosus

Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. Discontinue Protonix 40 mg and refer to a specialist for evaluation if symptoms suggestive of CLE or SLE occur.

Protonix 40 mg in Special Populations

Special considerations should be taken when prescribing Protonix 40 mg to certain patient populations:

Pregnancy

Available data from published observational studies in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. However, there are no adequate and well-controlled studies in pregnant women. Protonix 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation

Pantoprazole has been detected in human breast milk. The clinical relevance of this finding is not known. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Protonix 40 mg and any potential adverse effects on the breastfed child from pantoprazole or from the underlying maternal condition.

Pediatric Use

Safety and effectiveness of Protonix 40 mg have been established in pediatric patients 5 years and older for short-term treatment of erosive esophagitis associated with GERD. Use of Protonix 40 mg in this age group is supported by extrapolation of results from adequate and well-controlled studies in adults and safety and pharmacokinetic studies performed in pediatric patients.

Geriatric Use

In short-term US clinical trials, erosive esophagitis healing rates in the 107 elderly patients (≥65 years old) treated with Protonix 40 mg were similar to those found in patients under the age of 65. The incidence rates of adverse reactions and laboratory abnormalities in patients aged 65 years and older were similar to those associated with patients younger than 65 years of age.

This comprehensive guide to Protonix 40 mg provides valuable information on its uses, dosage guidelines, potential side effects, drug interactions, and important precautions. However, it’s crucial to remember that this information does not replace professional medical advice. Always consult with a healthcare provider for personalized recommendations and guidance regarding the use of Protonix 40 mg or any other medication.

Pantoprazole Dosage Guide + Max Dose, Adjustments

Print

Save

Medically reviewed by Drugs.com. Last updated on Dec 26, 2022.

Applies to the following strengths: 40 mg; 20 mg

Usual Adult Dose for:

• Erosive Esophagitis
• Gastroesophageal Reflux Disease
• Zollinger-Ellison Syndrome
• Pathological Hypersecretory Conditions

Usual Pediatric Dose for:

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Erosive Esophagitis

Treatment: 40 mg orally once a day

• Duration of therapy: 8 weeks

Maintenance: 40 mg orally once daily

Comments:

• If patients are not healed after 8 weeks or erosive esophagitis (EE) recurs with the oral formulation, treatment for another 8 weeks may be considered.
• Controlled studies using the oral formulation for maintenance did not extend beyond 12 months.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Maintenance of healing of EE

Usual Adult Dose for Gastroesophageal Reflux Disease

Oral: 40 mg orally once a day

• Duration of therapy: 8 weeks

Parenteral: 40 mg via IV infusion once a day, given over at least 2 minutes OR over 15 minutes

• Duration of therapy: 7 to 10 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation has not been studied for longer than 10 days.
• Safety and efficacy for uses otherwise described (e.g., life-threatening gastrointestinal bleeds) are not available; however, use of this drug at 40 mg/day doses did not raise gastric pH to sufficient levels to contribute to the treatment of life-threatening conditions.
• If patients are not healed after 8 weeks with the oral formulation, treatment for another 8 weeks may be considered.

Uses:

• Short-term treatment of gastroesophageal reflux disease (GERD) in patients with a history of erosive esophagitis
• Reduction of relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD

Usual Adult Dose for Zollinger-Ellison Syndrome

Oral: 40 mg orally 2 times a day

• Maximum dose: 240 mg/day

Parenteral:

• Initial dose: 80 mg via IV infusion every 12 hours, given over at least 2 minutes OR over 15 minutes
• Maintenance dose: 80 mg via IV infusion every 8 to 12 hours, given over at least 2 minutes OR over 15 minutes
• Maximum dose: 240 mg/day
• Maximum duration of therapy: 6 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation for longer than 6 days and/or with doses higher than 240 mg has not been adequately studied.
• Patients may be vulnerable to increased acid production despite a short period of loss of effective inhibition.
• Patients given the oral formulation should be continued on therapy for as long as clinically necessary.

Uses:

• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
• Pathological hypersecretion conditions, including Zollinger-Ellison syndrome

Usual Adult Dose for Pathological Hypersecretory Conditions

Oral: 40 mg orally 2 times a day

• Maximum dose: 240 mg/day

Parenteral:

• Initial dose: 80 mg via IV infusion every 12 hours, given over at least 2 minutes OR over 15 minutes
• Maintenance dose: 80 mg via IV infusion every 8 to 12 hours, given over at least 2 minutes OR over 15 minutes
• Maximum dose: 240 mg/day
• Maximum duration of therapy: 6 days

Comments:

• IV treatment should be discontinued once the patient is able to take an oral formulation.
• Use of the IV formulation for longer than 6 days and/or with doses higher than 240 mg has not been adequately studied.
• Patients may be vulnerable to increased acid production despite a short period of loss of effective inhibition.
• Patients given the oral formulation should be continued on therapy for as long as clinically necessary.

Uses:

• Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
• Pathological hypersecretion conditions, including Zollinger-Ellison syndrome

Usual Pediatric Dose for Erosive Esophagitis

5 years and older:
15 to less than 40 kg: 20 mg orally once a day
40 kg and greater: 40 mg orally once a day
Duration of therapy: Up to 8 weeks

Comment: Safety has not been established in treatment beyond 8 weeks.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Short-term treatment of GERD in patients with a history of EE

Usual Pediatric Dose for Gastroesophageal Reflux Disease

5 years and older:
15 to less than 40 kg: 20 mg orally once a day
40 kg and greater: 40 mg orally once a day
Duration of therapy: Up to 8 weeks

Comment: Safety has not been established in treatment beyond 8 weeks.

Uses:

• Short-term treatment in the healing and symptomatic relief of EE
• Short-term treatment of GERD in patients with a history of EE

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

IV: Data not available

Oral: Doses over 40 mg/day have not been studied in patients with liver impairment. No adjustment recommended.

Dose Adjustments

CYP450 2C19 Poor Metabolizers:
Adults: No adjustment recommended.
Pediatric patients: Oral dose reductions should be considered.

Pathological Hypersecretion (including Zollinger-Ellison syndrome):

• Acid output target range: Less than 10 mEq/h

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component, substituted benzimidazoles, or any of the ingredients
• Patients receiving rilpivirine-containing products

Safety and efficacy of oral formulations have not been established in patients younger than 5 years. The IV formulation is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Tablet formulations should be swallowed whole, without crushing/chewing; tablets may be taken with or without food.
• For patients unable to swallow a 40 mg tablet, two 20 mg tablets may be taken; however, the 40 mg oral suspension packet formulation should not be divided to create two-20 mg dosages.
• Oral suspension/granule formulations should be taken on an empty stomach, preferably 30 to 60 minutes before a meal.
• The granule formulation may be sprinkled into applesauce or mixed into a small volume of either apple juice or orange juice and swallowed immediately. This drug may be mixed with apple juice and administered via nasogastric tube.

Storage requirements: The manufacturer product information should be consulted.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

IV compatibility: The manufacturer product information should be consulted.

General:

• This drug may be used concomitantly with antacids without affecting the absorption.
• Reflux symptoms may take 2 to 3 days to improve after initiation.
• Rapid acid control may be achieved within an hour at an IV dose of 160 mg.

Monitoring:

• HEPATIC: Liver function tests, especially in patients with impaired liver function
• METABOLIC: Magnesium levels, especially in patients taking other drugs that could result in hypomagnesemia or those on long-term therapy; Vitamin B12 levels, especially in patients on long-term therapy
• MUSCULOSKELETAL: Bone fractures, especially in patients at high-risk for osteoporosis-related events
• RENAL: Renal function tests

Patient advice:

• Advise patients to avoid taking concomitant proton pump inhibitors and/or h3 antagonists during treatment.
• If using this drug to treat H pylori, tell patients that it is important to complete the full regimen.
• Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, Clostridium difficile, or systemic cutaneous lupus erythematosus occur.
• Patients should be told that treatment may not provide immediate relief and that they should not take this drug for prophylaxis. Symptomatic relief may occur after 1 day of treatment, but patients should continue treatment for the full duration to achieve complete symptom control.
• Inform patients that this drug may cause dizziness or blurred vision, and they should avoid driving or operating machinery if these side effects occur.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.

Frequently asked questions

• Pantoprazole vs. omeprazole: What’s the difference between them?
• Can you take pantoprazole 40 mg twice a day?
• How long can I take pantoprazole?
• Does pantoprazole cause bloating?

More about pantoprazole

• Check interactions
• Compare alternatives
• Pricing & coupons
• Reviews (415)
• Drug images
• Side effects
• Patient tips
• During pregnancy
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Patient resources

• Drug Information
• Pantoprazole (Intravenous) (Advanced Reading)
• Pantoprazole (Oral) (Advanced Reading)
• Pantoprazole Delayed-Release Granules
• Pantoprazole Delayed-Release Tablets
• Pantoprazole Injection

Other brands

Protonix, Protonix IV

Professional resources

• Prescribing Information

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Dumping Syndrome
• Duodenal Ulcer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Pantoprazole Interactions Checker – Drugs.com

Print

Save

There are 163 drugs known to interact with
pantoprazole, along with
4 disease interactions.

Of the total drug interactions,
16 are major, 128 are moderate, and 19 are minor.

Does pantoprazole interact with my other drugs?

Enter other medications to view a detailed report.

• View all 163 medications that may interact with pantoprazole
• View pantoprazole disease interactions (4)

Most frequently checked interactions

View interaction reports for pantoprazole and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• Aspir 81 (aspirin)
• Aspirin Low Strength (aspirin)
• Benadryl (diphenhydramine)
• CoQ10 (ubiquinone)
• Crestor (rosuvastatin)
• Cymbalta (duloxetine)
• Eliquis (apixaban)
• Fish Oil (omega-3 polyunsaturated fatty acids)
• Flonase (fluticasone nasal)
• Lasix (furosemide)
• Lexapro (escitalopram)
• Lipitor (atorvastatin)
• Lyrica (pregabalin)
• Metoprolol Succinate ER (metoprolol)
• Metoprolol Tartrate (metoprolol)
• MiraLAX (polyethylene glycol 3350)
• Norco (acetaminophen / hydrocodone)
• Plavix (clopidogrel)
• ProAir HFA (albuterol)
• Singulair (montelukast)
• Symbicort (budesonide / formoterol)
• Synthroid (levothyroxine)
• Tylenol (acetaminophen)
• Vitamin B12 (cyanocobalamin)
• Vitamin C (ascorbic acid)
• Vitamin D2 (ergocalciferol)
• Vitamin D3 (cholecalciferol)
• Xanax (alprazolam)
• Xarelto (rivaroxaban)
• Zyrtec (cetirizine)

Pantoprazole disease interactions

There are 4 disease interactions with pantoprazole which include:

• C. diff
• liver disease
• bone fractures
• hypomagnesemia

Report options

Loading…

QR code containing a link to this page

More about pantoprazole

• pantoprazole consumer information
• Compare alternatives
• Pricing & coupons
• Reviews (415)
• Drug images
• Side effects
• Dosage information
• Patient tips
• During pregnancy
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Dumping Syndrome
• Duodenal Ulcer

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website